| abstract |
Selective depletion of hematopoietic cells according to the invention of antibodies-drug conjugates (ADCs) that specifically bind to CD134 or CD278 prevents and treats graft-versus-host and autoimmune diseases, such as those resulting from transplant therapy. Provide a method. The compositions and methods described herein can be used to treat a variety of pathologies, including autoimmune diseases, stem cell disorders, and other blood conditions. |